These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 25450861)

  • 1. NFκB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms.
    Frasor J; El-Shennawy L; Stender JD; Kastrati I
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 3(0 3):235-9. PubMed ID: 25450861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer.
    Zhou Y; Yau C; Gray JW; Chew K; Dairkee SH; Moore DH; Eppenberger U; Eppenberger-Castori S; Benz CC
    BMC Cancer; 2007 Apr; 7():59. PubMed ID: 17407600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The NFkappaB pathway and endocrine-resistant breast cancer.
    Zhou Y; Eppenberger-Castori S; Eppenberger U; Benz CC
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S37-46. PubMed ID: 16113098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on the Role of NFκB in Promoting Aggressive Phenotypes of Estrogen Receptor-Positive Breast Cancer.
    Smart E; Semina SE; Frasor J
    Endocrinology; 2020 Oct; 161(10):. PubMed ID: 32887995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NF{kappa}B cooperativity at adjacent response elements.
    Pradhan M; Bembinster LA; Baumgarten SC; Frasor J
    J Biol Chem; 2010 Oct; 285(41):31100-6. PubMed ID: 20705611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The interaction between ER and NFκB in resistance to endocrine therapy.
    Sas L; Lardon F; Vermeulen PB; Hauspy J; Van Dam P; Pauwels P; Dirix LY; Van Laere SJ
    Breast Cancer Res; 2012 Aug; 14(4):212. PubMed ID: 22963717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NFκB signaling is important for growth of antiestrogen resistant breast cancer cells.
    Yde CW; Emdal KB; Guerra B; Lykkesfeldt AE
    Breast Cancer Res Treat; 2012 Aug; 135(1):67-78. PubMed ID: 22527100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PHLDA1 expression is controlled by an estrogen receptor-NFκB-miR-181 regulatory loop and is essential for formation of ER+ mammospheres.
    Kastrati I; Canestrari E; Frasor J
    Oncogene; 2015 Apr; 34(18):2309-16. PubMed ID: 24954507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Strategy to Co-target Estrogen Receptor and Nuclear Factor κB Pathways with Hybrid Drugs for Breast Cancer Therapy.
    Kastrati I; Siklos MI; Brovkovych SD; Thatcher GRJ; Frasor J
    Horm Cancer; 2017 Jun; 8(3):135-142. PubMed ID: 28396978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
    Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
    Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.
    Clarke R; Liu MC; Bouker KB; Gu Z; Lee RY; Zhu Y; Skaar TC; Gomez B; O'Brien K; Wang Y; Hilakivi-Clarke LA
    Oncogene; 2003 Oct; 22(47):7316-39. PubMed ID: 14576841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective pressure of endocrine therapy activates the integrated stress response through NFκB signaling in a subpopulation of ER positive breast cancer cells.
    Semina SE; Pal P; Kansara NS; Huggins RJ; Alarid ET; Greene GL; Frasor J
    Breast Cancer Res; 2022 Mar; 24(1):19. PubMed ID: 35264224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers.
    Zhou Y; Eppenberger-Castori S; Marx C; Yau C; Scott GK; Eppenberger U; Benz CC
    Int J Biochem Cell Biol; 2005 May; 37(5):1130-44. PubMed ID: 15743683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer.
    Girault I; Bièche I; Lidereau R
    Maturitas; 2006 Jul; 54(4):342-51. PubMed ID: 16822624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.
    Gökmen-Polar Y; Toroni RA; Hocevar BA; Badve S; Zhao Q; Shen C; Bruckheimer E; Kinch MS; Miller KD
    Breast Cancer Res Treat; 2011 Jun; 127(2):375-84. PubMed ID: 20602165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
    Cui X; Schiff R; Arpino G; Osborne CK; Lee AV
    J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780).
    Gu Z; Lee RY; Skaar TC; Bouker KB; Welch JN; Lu J; Liu A; Zhu Y; Davis N; Leonessa F; Brünner N; Wang Y; Clarke R
    Cancer Res; 2002 Jun; 62(12):3428-37. PubMed ID: 12067985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological mechanisms and clinical implications of endocrine resistance in breast cancer.
    Giuliano M; Schifp R; Osborne CK; Trivedi MV
    Breast; 2011 Oct; 20 Suppl 3():S42-9. PubMed ID: 22015292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
    Morrissey JJ; Raney S
    Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.